
浏览全部资源
扫码关注微信
1.750004 银川,宁夏医科大学研究生院
2.712000 陕西 咸阳, 咸阳市中心医院神经内科
3.750004 银川,宁夏医科大学总医院神经内科
4.750004 银川,宁夏医科大学颅脑实验室
[陈桂生,E-mail:chenguisheng1967@163.com CHEN Guisheng, E-mail: chenguisheng1967@163.com
收稿:2021-05-23,
修回:2021-06-28,
纸质出版:2021-11-30
移动端阅览
康雪, 李海洋, 孙阳阳, 等. 卵圆孔未闭合并隐源性卒中介入封堵与药物的疗效对比[J]. 第三军医大学学报, 2021,43(22):2468-2473.
Xue KANG, Haiyang LI, Yangyang SUN, et al. Efficacy of interventional closure versus drug therapy for patent foramen ovale with cryptogenic stroke[J]. Journal of Third Military Medical University, 2021, 43(22): 2468-2473.
康雪, 李海洋, 孙阳阳, 等. 卵圆孔未闭合并隐源性卒中介入封堵与药物的疗效对比[J]. 第三军医大学学报, 2021,43(22):2468-2473. DOI: 10.16016/j.1000-5404.202105100.
Xue KANG, Haiyang LI, Yangyang SUN, et al. Efficacy of interventional closure versus drug therapy for patent foramen ovale with cryptogenic stroke[J]. Journal of Third Military Medical University, 2021, 43(22): 2468-2473. DOI: 10.16016/j.1000-5404.202105100.
目的
2
比较介入封堵与药物治疗两种方式对卵圆孔未闭(patent foramen ovale
PFO)合并隐源性卒中(cryptogenic stroke
CS)的疗效。
方法
2
回顾性收集2015年1月至2019年8月于宁夏医科大学总医院神经内科住院的脑梗死或短暂性脑缺血发作(transient ischemic attack,TIA)合并PFO患者病例资料167例,其中PFO介入封堵+抗栓药物治疗80例,仅药物治疗(口服抗血小板聚集
或抗凝药物)87例,平均随访31.6(12~67)个月。根据是否发生终点事件(复发脑梗死、复发TIA和死亡)分为有终点事件组(
n
=24)和无终点事件组(
n
=143)。用单因素分析比较两组患者的一般资料,多因素分析筛选患者终点事件复发的独立危险因素;结合受试者工作特征(ROC)曲线分析模型,评估其预测价值。
结果
2
手术组终点事件的复发率明显低于药物组(χ
2
=10.959,
P
=0.001),且PFO为中、大量分流的患者获益较多(χ
2
=10.26,
P
=0.001)。单因素结果显示,治疗方法、随访时间及阻塞性睡眠呼吸暂停(obstructive sleep apnea
OSA)病史对有无终点事件发生方面差异有统计学意义(
P
<
0.05)。Logistic回归分析显示,影响预后的独立危险因素包括药物治疗(
OR
=8.958,
P
=0.001,95%
CI
:2.475~32.422)、随访时间(
OR
=1.041,
P
=0.013,95%
CI
:1.009~1.075)及OSA病史(
OR
=8.117,
P
=0.001,95%
CI
:2.247~29.324)。ROC曲线分析显示:以药物治疗、随访时间及OSA病史为变量的模型的曲线下面积为0.813(95%
CI
:0.737~0.889,
P
<
0.001);以药物治疗和OSA病史为变量的模型的曲线下面积为0.767(95%
CI
:0.677~0.856,
P
<
0.001);以药物治疗和随访时间为变量的模型的曲线下面积为0.764(95%
CI
:0.674~0.853,
P
<
0.001)。
结论
2
对于PFO合并CS的患者,PFO介入封堵可降低终点事件的复发风险,且PFO为中、大量分流的患者受益较大。积极干预OSA对终点事件的复发有一定的预防作用。
Objective
2
To compare the efficacy of interventional closure versus drug therapy in treatment of patent foramen ovale (PFO) complicated with cryptogenic stroke (CS).
Methods
2
Clinical data of 167 patients with cerebral infarction or transient ischemic attack (TIA) complicated with PFO admitted in the Department of Neurology
General Hospital of Ningxia Medical University from January 2015 to August 2019 were collected and analyzed retrospectively. Among them
80 (the surgery group) underwent PFO interventional closure and antithrombotic drug administration
and the other 87 (the drug group) only received drug therapy (oral antiplatelet aggregation or anticoagulant drugs). All the patients were followed up for an a
verage of 31.6 (12~67) months. According to occurrence of endpoint events (recurrent cerebral infarction
recurrent TIA and death)
the patients were divided into endpoint event group (
n
=24) and non-endpoint event group (
n
=143). Univariate analysis was used to compare the general data between the 2 groups of patients
and multivariate analysis was used to screen independent risk factors for the recurrence of the endpoint events. Receiver operating characteristic (ROC) curve analysis was combined to evaluate the predictive values of obtained risk factors.
Results
2
The recurrence rate of the endpoint events was significantly lower in the surgery group than the drug group (
Chi
-square=10.959
P
=0.001)
and the patients with moderate and large shunts of PFO benefited more (
Chi
-square=10.26
P
=0.001). Univariate analysis showed that the treatment method
follow-up time and history of obstructive sleep apnea (OSA) had statistical significances in the occurrence of endpoint events (
P
<
0.05); Multivariate logistic regression analysis showed that the independent risk factors affecting the prognosis of patients were drug therapy (
OR
=8.958
P
=0.001
95%
CI
: 2.475~32.422)
follow-up time (
OR
=1.041
P
=0.013
95%
CI
: 1.009~1.075) and a history of OSA (
OR
=8.117
P
=0.001
95%
CI
: 2.247~29.324). ROC curve analysis showed that the area under the curve was 0.813 (95%
CI
: 0.737 to 0.889
P
<
0.001) for the model with drug therapy
follow-up time
and OSA history as variables. The area under the curve was 0.767 (95%
CI
: 0.677~0.856
P
<
0.001) for the model with drug therapy and OSA history as variables
and 0.764 (95%
CI
: 0.674~0.853
P
<
0.001) f
or the model with drug therapy and follow-up time as variables.
Conclusion
2
For patients with PFO complicated with CS
interventional closure can reduce the risk of recurrence of the end point events
and the patients with moderate or large number of shunts of PFO benefit more. Active OSA intervention have a certain preventive effect on the recurrence of the endpoint events.
WANG W Z, JIANG B, SUN H X, et al . Prevalence, incidence, and mortality of stroke in China[J ] . Circulation, 2017, 135(8): 759-771. DOI: 10.1161/circulationaha.116.025250.
SAVER J L, MATTLE H P, THALER D. Patent foramen ovale closure versus medical therapy for cryptogenic ischemic stroke: a topical review[J]. Stroke, 2018, 49(6): 1541-1548. DOI: 10.1161/STROKEAHA.117.018153.
MIRANDA B, FONSECA A C, FERRO J M. Patent foramen ovale and stroke[J]. J Neurol, 2018, 265(8): 1943-1949. DOI: 10.1007/s00415-018-8865-0.
SAVER J L. Cryptogenic stroke[J]. N Engl J Med, 2016, 375(11): e26. DOI: 10.1056/nejmc1609156.
张玉顺, 蒋世良, 朱鲜阳. 卵圆孔未闭相关卒中预防中国专家指南[J]. 心脏杂志, 2021, 33(1): 1-10.
ZHANG Y S, JIANG S L, ZHU X Y. Chinese expert guidelines for the prevention of patent foramen ovale-associated stroke[J]. Chin Heart J, 2021, 33(1): 1-10.
GOEL S, PATEL S, ZAKIN E, et al . Patent foramen ovale closure versus medical therapy for cryptogenic stroke: an updated systematic review and meta-analysis[J ] . Indian Heart J, 2019, 71(6): 446-453. DOI: 10.1016/j.ihj.2019.10.002.
SØNDERGAARD L, KASNER S E, RHODES J F, et al . Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke[J ] . N Engl J Med, 2017, 377(11): 1033-1042. DOI: 10.1056/nejmoa1707404.
SAVER J L, CARROLL J D, THALER D E, et al . Long-term outcomes of patent foramen ovale closure or medical therapy after stroke[J ] . N Engl J Med, 2017, 377(11): 1022-1032. DOI: 10.1056/nejmoa1610057.
MAS J L, DERUMEAUX G, GUILLON B, et al . Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke[J ] . N Engl J Med, 2017, 377(11): 1011-1021. DOI: 10.1056/NEJMoa1705915.
JASPER R, BLANKENSHIP J C. Patent foramen ovale closure to prevent secondary neurologic events[J]. Eur J Intern Med, 2017, 44: 1-11. DOI: 10.1016/j.ejim.2017.06.015.
SINGH H S, KATCHI F, NAIDU S S. PFO closure for cryptogenic stroke[J]. Cardiol Rev, 2017, 25(4): 147-157. DOI: 10.1097/CRD.0000000000000148.
JOHANSSON M C, HELGASON H, DELLBORG M, et al . Sensitivity for detection of patent foramen ovale increased with increasing number of contrast injections: a descriptive study with contrast transesophageal echocardiography[J ] . J Am Soc Echocardiogr, 2008, 21(5): 419-424. DOI: 10.1016/j.echo.2007.08.030.
王华, 刘夏天, 鲁建兴, 等. 经食管超声心动图与经胸超声心动图造影检查对卵圆孔未闭的诊断价值[J]. 中国医刊, 2020, 55(2): 221-223.
WANG H, LIU X T, LU J X, et al . The diagnostic value of transesophageal echocardiography and transthoracic echocardiography for patent foramen ovale[J ] . Chin J Med, 2020, 55(2): 221-223.
彭斌, 刘鸣, 崔丽英. 中国急性缺血性脑卒中诊治指南2018[J]. 中华神经科杂志, 2018, 51(9): 666-682. DOI: 10.3760/cma.j.issn.1006-7876.2018.09.004.
PENG B, LIU M, CUI L Y. Chinese guidelines for diagnosis and treatment of acute ischemic stroke 2018[J]. Chin J Neurol, 2018, 51(9): 666-682. DOI: 10.3760/cma.j.issn.1006-7876.2018.09.004.
ELGENDY A Y, SAVER J L, AMIN Z, et al . Proposal for updated nomenclature and classification of potential causative mechanism in patent foramen ovale-associated stroke[J ] . JAMA Neurol, 2020, 77(7): 878-886. DOI: 10.1001/jamaneurol.2020.0458.
邵珲, 杜亚娟, 宋强, 等. 卵圆孔未闭(右向左分流)与隐源性缺血性脑卒中的关系及筛检评价[J]. 心脏杂志, 2020, 32(5): 502-505,512.
SHAO H, DU Y J, SONG Q, et al . Relationship and screening evaluation between patent foramen ovale (right-to-left shunt) and cryptogenic ischemic stroke[J ] . Chin Heart J, 2020, 32(5): 502-505, 512.
THALER D. Patent foramen ovale in older patients with cryptogenic stroke or transient ischaemic attack[J]. Lancet Neurol, 2018, 17(7): 573-574. DOI: 10.1016/S1474-4422(18)30198-4.
曹月诚, 羡海英, 石秋林, 等. 卵圆孔未闭封堵术在少量右向左分流患者中的临床疗效评价[J]. 心血管病学进展, 2019, 40(7): 1062-1066. DOI: 10.16806/j.cnki.issn.1004-3934.2019.07.024.
CAO Y C, XIAN H Y, SHI Q L, et al . Clinical evaluation of patent foramen ovale closure in slight right-to-left shunt patients[J ] . Adv Cardiovasc Dis, 2019, 40(7): 1062-1066. DOI: 10.16806/j.cnki.issn.1004-3934.2019.07.024.
KASNER S E, KASE C S, TURAN T N, et al . Characterization of recurrent strokes with and without patent foramen ovale closure[J ] . J Am Coll Cardiol, 2018, 72(20): 2542-2544. DOI: 10.1016/j.jacc.2018.08.2175.
OZDEMIR O, BELETSKY V, HACHINSKI V, et al . Cerebrovascular events on awakening, patent foramen ovale and obstructive sleep apnea syndrome[J ] . J Neurol Sci, 2008, 268(1/2): 193-194. DOI: 10.1016/j.jns.2007.11.010.
MAN H H, XU Y T, ZHAO Z M, et al . The coexistence of a patent foramen ovale and obstructive sleep apnea may increase the risk of wake-up stroke in young adults[J ] . Technol Health Care, 2019, 27(S1): 23-30. DOI: 10.3233/T HC-199004.
何权瀛. 卵圆孔未闭在阻塞性睡眠呼吸暂停引发的多种脑血管疾病中的作用[J]. 中华医学杂志, 2020, 100(36): 2808-2812. DOI: 10.3760/cma.j.cn112137-20200604-01772.
HE Q Y. The role of patent foramen ovale in various cerebrovascular diseases caused by obstructive sleep apnea[J]. Natl Med J China, 2020, 100(36): 2808-2812. DOI: 10.3760/cma.j.cn112137-20200604-01772.
PELLATON C, HEINZER R, MICHEL P, et al . Patent foramen ovale and obstructivesleep apnoea: from pathophysiology to diagnosis of a potentially dangerous association[J ] . Arch Cardiovasc Dis, 2011, 104(4): 242-251. DOI: 10.1016/j.acvd.2010.12.008.
XIE A L, SKATRUD J B, DEMPSEY J A. Effect of hypoxia on the hypopnoeic and apnoeic threshold for CO 2 in sleeping humans[J ] . J Physiol, 2001, 535(1): 269-278. DOI: 10.1111/j.1469-7793.2001.00269.x.
AGNOLETTI G, ISERIN L, LAFONT A, et al . Obstructive sleep apnoea and patent foramen ovale: successful treatment of symptoms by percutaneous foramen ovale closure[J ] . J Interv Cardiol, 2005, 18(5): 393-395. DOI: 10.1111/j.1540-8183.2005.00072.x.
0
浏览量
0
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621